These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Chen JJ; Swope DM J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398 [TBL] [Abstract][Full Text] [Related]
45. [Rasagiline is not for all Parkinson disease patients: the ADAGIO study]. van Laar T; Boon AJ; Bloem BR Ned Tijdschr Geneeskd; 2010; 154():A2496. PubMed ID: 20977789 [TBL] [Abstract][Full Text] [Related]
46. A case of rasagiline-induced spontaneous orgasms in a female patient. Uca AU; Kozak HH Parkinsonism Relat Disord; 2014 Aug; 20(8):929-30. PubMed ID: 24837642 [No Abstract] [Full Text] [Related]
47. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. White WB; Salzman P; Schwid SR; Hypertension; 2008 Sep; 52(3):587-93. PubMed ID: 18678789 [TBL] [Abstract][Full Text] [Related]
48. [Hypersexuality during use of levodopa]. van Puijenbroek EP; Diemont WL Ned Tijdschr Geneeskd; 2003 May; 147(20):990. PubMed ID: 12784535 [No Abstract] [Full Text] [Related]
49. Transdermal selegiline (Emsam). Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292 [No Abstract] [Full Text] [Related]
51. [Revision of the treatment strategy in Parkinson disease]. Staal-Schreinemachers AL; Wesseling H; Lakke JP Ned Tijdschr Geneeskd; 1986 May; 130(20):914-8. PubMed ID: 3724865 [No Abstract] [Full Text] [Related]
52. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients]. Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842 [TBL] [Abstract][Full Text] [Related]
53. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
54. Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report. Ibrahim FA; Rashid F; Hussain AA; Alawadi F; Bashier A J Med Case Rep; 2017 Feb; 11(1):29. PubMed ID: 28148284 [TBL] [Abstract][Full Text] [Related]
55. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ; Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083 [TBL] [Abstract][Full Text] [Related]
56. Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. Levy A; Lang AE Can J Neurol Sci; 2017 Jul; 44(4):447-448. PubMed ID: 28767029 [No Abstract] [Full Text] [Related]
57. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
58. Drug selection and timing of initiation of treatment in early Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579 [TBL] [Abstract][Full Text] [Related]
59. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Mandel S; Weinreb O; Amit T; Youdim MB Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677 [TBL] [Abstract][Full Text] [Related]